bispecific T-cell engager, BiTE, BiTE therapy, multiple myeloma
Development and future potential of the BiTE (bispecific T-cell engager) platform
Immuno-oncology is a way to treat cancer by using the body's immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds a patient's own T cells to cancer cells. Because BiTE techno..
Cartesian Therapeutics, Descartes-08, Lancet, myasthenia gravis
Rare autoimmune disorder myasthenia gravis treated by CAR-T therapy
July 2023: Evidence from a small-scale clinical trial shows that myasthenia gravis, an autoimmune disorder of the nervous system, could be treated with a variation of CAR-T, an advanced blood cancer immunotherapy. The modifie..
Pfizer, TALAPRO-2, Talazoparib
Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
CD20, Columvi, DLBCL, Genentech
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
abiraterone, Lynparza, olaparib, prednisone
Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspected deleterious BRCA-mutated (BR..
DuoBody, Epcoritamab, epkinly, Genmab, IgG1-bispecific antibody
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL that co..
lymphoma car t cell therapy, lymphoma trials
A study of chimeric antigen receptor T lymphocytes (CAR-T) in the treatment of relapsed and refractory non-Hodgkin lymphoma
Detailed Description: This is a single-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collection of autologous lymphocytes. Once..
anti-BCMA, BCMA CAR-T, chimeric antigen receptor T cell therapy, China, Immune thrombocytopenia, ITP
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
March 2023: Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part o..
Bone marrow transplant in Iran
Bone marrow transplant is one of the services of Cancerfax, which is provided by the best surgeons, along with accommodation, a translator, a companion nurse, and a city tour at an affordable price in Iran. What is leukemia? ..
arrythmia, Medtronic International, MICRA pacemaker implants, Sheba Medical Center
Sheba medical center became the first Israeli facility to receive permission from Medtronic International to train medical professionals on MICRA pacemaker implants
RAMAT GAN, Israel – June, 2022 – Sheba Medical Center, Israel’s largest medical center and a Newsweek top-10 ranked world’s best hospital for the last four years, announced today that it has been authorized by Medtronic In..